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both durability and 1-year functional results of pulmonary
homograft valves in juvenile sheep
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Objective: The juvenile sheep functional valve chronic implant calcification model was used to compare long-
term calcification rates, functional performance, and durability for 3 types of right ventricular outflow tract
implants: classically cryopreserved homografts and 2 decellularized pulmonary valved conduits.
Methods: Fifteen juvenile sheep were randomly assigned to one of 3 study arms and underwent pulmonary valve
replacement. The arms included the following: (1) cryopreserved ovine pulmonary valves; (2) cryopreserved, de-
cellularized, saline (1C–10C)–stored ovine pulmonary valves; and (3) cryopreserved, decellularized, glycerol-
ized (80C) stored ovine pulmonary valves. Animal growth, serial echocardiographic results (with valve
performance assessment), dimensions, and tissue-specific calcification measurements were compared with pre-
explant angiographic analysis and right ventricular outflow tract pressure measurements, cardiac magnetic reso-
nance imaging, specimen radiographic analysis, gross explant pathology, and histopathology. Parametric and
nonparametric statistical analysis were performed.
Results: All but 2 study animals receiving implants thrived postoperatively, with similar growth rates, explant
valve dimensions, ventricular functions, cardiac output, and indices during the study. As determined by means
of echocardiographic analysis, 3 animals in arm 1 (and one in arm 2) had leaflet dysfunction. Valve regurgitation
was recognized in 1 survivor each from both arms 1 and 2. Although 1 arm 1 animal died with calcified subacute
bacterial endocarditis, and the other 4 had leaflet and conduit wall calcification by the time of death, no arm 2 or
arm 3 animals demonstrated leaflet calcium, and no arm 3 and only 1 arm 2 animals had calcium in the conduit
wall over the entire year, as determined with any measurement method. All cryopreserved conduit walls had cal-
cium by 20 weeks, whereas only 1 of 10 decellularized conduits (arms 2 plus 3) had wall calcium.
Conclusion:Cryopreserved–decellularized–glycerolized valves retained normal valve function, with absent leaf-
let and minimal wall calcifications 1 year postoperatively, as opposed to classically cryopreserved allografts.
These results might be predictive of the prolonged durability and functionality of a cryopreserved–decellular-
ized–glycerolized allograft valve.
CONGENITAL HEART DISEASEThe Journal of Thoracic andrendering the valve essentially acellular 9 to 12 months after
implantation.1 Retained antigenic, apoptotic, necrotic, donor
cells/cellular debris lead to calcification, chronic inflamma-
tion, or both, promoting valve failure.2-5 Efficiently decellu-
larized, tissue-engineered homografts might prolong
durability by reducing recipient inflammation, immune re-
sponses, fibrous scarring, and calcification, ultimately de-
creasing the number of patients requiring reconstructive
cardiac surgery.6
The juvenile sheep chronic valve implant model is an
excellent predictor of the durability and performance of
biologic heart valves as affected by calcification.7,8 This
model was used in this study to compare long-term calcifi-
cation rates, functional performance, and putative durability
between classically cryopreserved allograft valves (arm 1)
and cryopreserved–decellularized allograft pulmonary
valve conduits preserved by means of 2 different methods.
Arm 2 was comprised of decellularized valves stored in sa-
line (4C), and arm 3 consisted of decellularized valves
stored in glycerol (80C) for at least 2 weeks before
implantation.Supplemental material is available online.
Cryopreserved homograft valves retain donor cells with
varying degrees of metabolic activity. Cells become apopto-
tic as a result of harvest, transport, and cryopreservation,
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DAbbreviations and Acronyms
ANOVA ¼ analysis of variance
EOA ¼ effective orifice area
MRI ¼ magnetic resonance imaging
PRA ¼ panel reactive antibody
MATERIALS AND METHODS
Homograft Harvest and Processing
Donor valves were harvested from sheep of analogous size, age, and
weight but from different breeding stock than recipients. All valves were ob-
tained by means of aseptic excision and in a manner similar to tissue harvest
procedures.9 Warm ischemic time was less than 1 hour. Each heart was
placed in Lactated Ringers solution containing antibiotics and shipped to
LifeNet Health (Virginia Beach, Va) on wet ice at 1C to 10C. Cold ische-
mic time before processing did not exceed 24 hours.
On receipt, pulmonary valves were dissected and disinfected by using
standard clinical methods (4C for 24 2 hours with cefoxitin, lincomycin,
polymyxin B, and vancomycin antibiotics). Subsequently, valves were in-
cubated in RPMI 1640 containing 10% dimethyl sulfoxide and 10% fetal
calf serum and cryopreserved at1C/min by using a computer-controlled
freezing profile. Valves were then held in vapor-phase liquid nitrogen for
at least 48 hours before decellularization.10
Decellularization
Before decellularization, valves were thawed and diluted of cryoprotec-
tant by using a standard clinical protocol. The valve conduits were decellu-
larized by LifeNet Health as in Appendix E1.
Sheep Chronic Implant Model
The investigational protocol used in this study was approved by the an-
imal care and use committee. The animals received humane care in compli-
ance with the principles stated in the ‘‘Guide for the care and use of
laboratory animals’’ (National Institutes of Health publication no. 85-23).
Fifteen juvenile, pre-estrus female domestic sheep (Ovis aries) of a Ram-
bouillet, North Country Cheviot, Suffolk breed mix (163  27.9 days of
age; range, 126–202 days of age) with body weights 30 to 40 kg were se-
lected as recipients. Age distribution for each arm was as follows: arm 1,
151.2 28.9 days (range, 126–196 days); arm 2, 149.0 20.5 days (range,
128–173 days); and arm 3, 190.4 10.9 days (range, 176–202 days). After
achievement of general anesthesia through a left thoracotomy and with car-
diopulmonary bypass support, the pulmonary valve was excised, and the
test valve was sutured into place as an interposition valved conduit. Animals
were matured as a herd for 1 year.
Serial Studies
The following assessments were performed before implantation and 10,
20, 35, and 52 weeks after valve implantation: animal size, echocardio-
graphic analysis, and panel reactive antibody (PRA) analysis.11 Other as-
sessments were performed 1 week before death.
Animal growth. Sheep growth was assessed by means of weight and
length measurements and then converted to body surface area by using the
Haycock formula.12
Echocardiographic analysis. Valve performance was evaluated
with transthoracic 2-dimensional echocardiographic and Doppler assess-
ments. Images were obtained in unsedated sheep held in the right lateral de-
cubitus position with a 2.5-MHz transducer and a SONOS 1000 platform
(Hewlett–Packard, Palo Alto, Calif). Echocardiographic protocols are fully
described in Appendix E2.908 The Journal of Thoracic and Cardiovascular SuPRA assay. Blood specimens were collected from the jugular veins of
the sheep. The full serum PRA protocol is included in Appendix E3.11
Pre-explantation Studies
One week before death (week 52), each surviving animal underwent car-
diac catheterization with right ventricular and pulmonary arterial angio-
graphic analysis. These techniques are included in Appendices E4 and
E5, respectively. All animals in arm 3 (and 1 in arm 1) also underwent car-
diac magnetic resonance imaging (MRI), as detailed in Appendix E6.
Valve Explant Studies
Gross examination and measurements. After necropsy, ex-
plants were examined macroscopically (with a dissecting microscope) and
radiographically (with an OEC 9600; General Electric, Milwaukee, Wis)
for calcification and gross abnormalities. Calcium was mapped on a stan-
dardized valve diagram, and leaflet morphology, mobility, and configura-
tion were recorded. Conduit dimensions were measured with calipers.
The valves were then fixed for histopathology.
Histopathology. Movat’s pentachrome, hematoxylin and eosin (Vec-
tor Laboratories, Burlingame, Calif), and either Alizarin red S or Von Kossa
staining was performed by using standard histologic methods. Immunohis-
tochemistry, confocal microscopy, electron microscopy, and quantitative
morphometrics were also performed and will be reported separately.
Statistics
For all variables, descriptive statistics (means and standard deviations for
continuous variables and proportions for categorical variables) were com-
puted. Echocardiographic variables were compared by using single-factor
analysis of variance (ANOVA). A general linear regression model was
used for repeated measures (eg, multiple time points). Multivariate analyses
included Pillai’s Trace, Wilks’ Lambda, Hotelling’s Trace, and Roy’s Larg-
est Root. The SPSS version 15.0 for Windows Statistical Package (SPSS,
Inc, Chicago, Ill) was used.
RESULTS
All but 2 study animals receiving implants thrived postop-
eratively. One arm 1 animal had bacterial endocarditis at 257
days. One arm 2 animal accidently hanged herself on a feed
trough on day 299. All arm 3 animals survived the full 52
weeks. The rate of animal growth was similar for all 3
arms (see Figure E1), with significant increases in body sur-
face area over time (ie, growth, P ¼ .006). The sheep dem-
onstrated no significant differences in growth curve shapes
over the study (P ¼ .145).
Echocardiographic Analysis
Peak and mean pressure gradients, effective orifice area
(EOA) and EOA index were not different among arms
over the study (see Table E1). Three animals in arm 1 (and
1 in arm 2) had leaflet dysfunction, whereas function re-
mained normal for all arm 3 animals. Any occurrence of
leaflet dysfunction in arm 1 valves was associated with
leaflet calcification. The arm 2 animal identified with leaflet
dysfunction demonstrated wall calcium by means of echo-
cardiographic analysis, angiographic analysis, and explant
macro-observations. Overall, 4 of 5 arm 1, 1 of 5 arm 2,
and 0 of 5 arm 3 animals had leaflet calcium, wall calcium,
or both, as determined by means of echocardiographicrgery c April 2009
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rect observations and specimen radiographs, the 1 arm 2
conduit positive for calcium by means of echocardiographic
analysis had the calcium arising from the distal suture line.
Comparing all arms by means of c2 analysis, leaflet cal-
cium was more often identified at death for arm 1 animals
(P¼ .032, Pearson’s test) and for arm 1 versus arm 3 animals
(P ¼ .038, Pearson’s test). The Pearson’s test detected
higher conduit wall calcium frequencies in arm 1 among
the arms (P ¼ .027), with a higher difference between
arms 1 and 3 (P¼ .010, Pearson’s test). Ventricular function
was not different among the arms.
Cardiac Catheterization and Angiographic Analysis
One-way ANOVA demonstrated no significant interarm
differences in cardiac output, index, Gorlin EOA, and Gorlin
EOA index measurements obtained by means of catheteriza-
tion (see Table E2). One-way ANOVA demonstrated inter-
group differences in right ventricular systolic, diastolic, and
mean pressures. Pulmonary artery systolic, diastolic, and
mean pressures also included statistical differences. How-
ever, in all of these instances, the absolute values were con-
sidered biologically benign. Mean transvalvular and peak
gradients remained low for all groups.
Angiographic analysis demonstrated regurgitation in 1 of
4 arm 1, 1 of 4 arm 2, and 0 of 5 arm 3 survivors. Anasto-
motic or conduit wall calcium was visualized in 2 of 4 arm
1, 1 of 4 arm 2, and 0 of 5 arm 3 sheep.
Explant Studies
Directly measured valve dimensions for age were compa-
rable among the 3 arms over the 52 weeks, excluding one
outlier in arm 2, which was also the sheep that had leaflet
dysfunction (see Table E3).
At necropsy, grafts were graded for leaflet or conduit wall
inflammation, inflammatory changes at suture lines, (eg,
pannus formation), graft fibrous scarring (sheathing and cap-
sule formation), gross stenosis or dilatation, and visible or
palpable presence of calcifications (Tables 1 and 2). By
means of c2 analysis, the arms were not different except
for the presence of calcification, for which the cryopreserved
valves were significantly more likely to have calcium at each
location in the conduits (Table 2; P ¼ .011, Pearson’s test);
graft fibrous scarring (Table 1; arm 1 scarring greater than
that of arms 2 and 3; P ¼ .027, Pearson’s test); and suture
line scarring (Table 1; arm 1 scarring greater than that of
arms 2 and 3; P ¼ .004, Pearson’s test). Thus arm 1 (cryo-
preserved) valves consistently graded poorly relative to the
decellularized groups.
Calcification
Cryopreserved valves tended to manifest greater calcifica-
tion over the study period, which is consistent with clinical
human experience. For example, by week 52, the functionalThe Journal of Thoracic and Cstudies demonstrated that all 4 animals in arm 1 and none in
arm 3 had calcium somewhere in the conduit, as determined
by means of either or both echocardiographic and angio-
graphic analysis. An additional animal in arm 1 (that had bac-
terial endocarditis and died) also demonstrated calcification
at its last echocardiographic examination (week 10). Assum-
ing that once identified calcium does not diminish over time,
all 5 animals in arm 1 had calcifications over the course of the
study; direct observation and specimen radiographs corre-
lated well, demonstrating that all cryopreserved conduits
had calcifications involving leaflets and conduit wall; and
no decellularized allograft leaflets (groups 2 and 3) had cal-
cium by 52 weeks, as assessed by means of all methods.
When echocardiographic analysis identified calcium, ex-
plant macro-observations, specimen radiographic analysis,
MRI, and angiographic analysis confirmed this result. How-
ever, explant macro-observatory and specimen radiographic
analysis were more sensitive, identifying calcifications in all
5 conduits in arm 1 (leaflets and wall), but echocardio-
graphic analysis failed to identify 2 of the 5 arm 1 leaflet cal-
cifications. By means of c2 analyses, arm 1 was consistently
more calcified than arms 2 and 3, although arm 2 was not
TABLE 1. Explant macro-observations other than calcifications
Variable No. Prob>c2 Inferences
Graft inflammation 14 .108 Treatments were
not significantly
different.
Adventitial inflammation 14 .260 Treatments were
not significantly
different.
Inflammation at suture
lines
14 .358 Treatments were
not significantly
different.
Graft scarring 14 .027 Arm 1 had a higher
incidence of scarring
than arms 2 and 3.
Suture line scarring 14 .004 Arm 1 had a higher
incidence of scarring
at suture lines
than arms 2 and 3.
Leaflet, annulus,
or conduit scarring
14 .379 Individual tests
were run for each
location. For each,
treatments were not
significantly different.
Gross stenosis
or dilation
14 .379 Individual tests
were run for each.
Treatments were not
significantly different.
BE of leaflets 15 .343 Treatments were
not significantly
different.
Nonparametric multivariate analyses (Pearson’s test) indicated treatments were differ-
ent at an a value of .05. Contingency c2 analyses were performed for each variable to
determine which categorical variables contributed to the overall significant difference
among treatments. BE, Bacterial endocarditis.ardiovascular Surgery c Volume 137, Number 4 909
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cium identified in the conduit wall (associated with the distal
suture line) in 1 case, the proximal suture lines in 2 cases,
and never in leaflets. By using direct observations, MRI,
and radiographic analysis, only 1 animal of arm 3 had calci-
fication, which occurred only at the proximal anastomosis
and did not involve the leaflets or conduit wall. It should
be noted that although arm 1 conduit wall calcification as
a categorical value was only marginally greater when as-
sessed by means of specimen radiographic analysis (Table
2, P¼ .078), the magnitude of this calcification as an ordinal
variable measured by means of direct observation (see Table
E4) was significantly worse for arm 1 among the 3 arms
(P¼ .023, 1-way ANOVA) and for arm 1 versus arm 3 alone
(P ¼ .011, 1-way ANOVA).
MRI
MRI analyses (performed on all 5 arm 3 and 1 arm 1
sheep) confirmed the findings of echocardiographic analysis
and cardiac catheterization for the following: (1) presence or
absence of calcification; (2) calcium deposition by location;
and (3) valve leaflet function parameters. No calcifications
or valve dysfunctions were identified by means of MRI
that were missed by the combination of the other assess-
ments (see Table 3).
PRA Assay
Scatter plots of the results for the ovine PRA assay (for
major histocompatibility complex I and II), representing
TABLE 2. Univariate analysis: Calcium amounts observed by means
of specimen radiographic analysis per location and by treatment.
Variable c2 Prob>c2
Inferences from
proportions
Calcium anywhere 9.100 .011 Arm 1 had a higher incidence
of calcium present (4/4) than
arms 2 (2/5) and 3 (0/5).
Distal anastomosis 11.200 .082 Treatments were not significantly
different.
STJ 14.000 .007 Arm 1 had a higher incidence of
STJ calcium (4/4) than arms 2
(0/5) and 3 (0/5).
Leaflets 9.545 .049 Arm 1 had a higher incidence of
leaflet calcium (4/4) than arms
2 (0/5) and 3 (0/5).
Annulus 14.000 .007 Arm 1 had a higher incidence of
annulus calcium (4/4) than arms
2 (0/5) and 3 (0/5).
Proximal suture 10.700 .098 Treatments were not significantly
different.
Conduit wall 11.356 .078 Treatments were not significantly
different.
Pearson c2 tests were used to determine whether there were significant differences in
calcium location by treatment. Indicated treatments were different at an a value of .05.
Proportions were used to determine which categorical variables contributed to the
overall significant difference among treatments. STJ, sinotubular junction.910 The Journal of Thoracic and Cardiovascular Surmean fluorescent intensity units over time for each arm,
are included in Figure E2. No biologically relevant trends
could be extracted from these data. Notably, sheep are inher-
ently immunochallenged, with strong bacterial loads consti-
tutively present in their blood and stomachs. None of the
animals received antibiotic treatments after implantation
(over the course of the year) to suppress baseline inflamma-
tory responsivity.
Histopathology
Histology indicated that significant recellularization oc-
curred in the conduit walls and the base of leaflets for decel-
lularized (arms 2 and 3) valves (Figures 1 and 2). The arm 3
leaflets were also inconsistently recellularized; however,
they appeared to stimulate less pannus formation (fibrous
sheathing) than was observed in the cryopreserved (arm 1)
control valves. The distribution of calcification for arm 3
valves, as monitored by using the other experimental
methods (eg, radiographic analysis and MRI), was sup-
ported by these histology results.
Immunohistochemistry suggested that the cells involved in
recellularization were consistent with a typical myofibroblast
phenotype, including the expression of a-smooth muscle ac-
tin and heat shock protein 47 (Figure 3).
DISCUSSION
The utility of the juvenile ovine cardiac valve chronic
implant model in assessing calcification potential for bio-
logic constructs placed in the circulation is well prece-
dented.7,8,10,13 The juvenile sheep chronic implant model
was developed by a joint US Food and Drug Administra-
tion–National Institutes of Health/National Heart, Lung,
and Blood Institute research effort in the late 1970s to es-
tablish a reliable animal marker to assess the calcification
TABLE 3. Summary of calcium identified by using 5 measurement
methods
Calcium identified anywhere
(no. of animals per arm)
Method of analysis Arm 1* Arm 2 Arm 3
Echocardiography 4 1 0
Radiography 4 2 1
Direct observation 4 2 1
Angiography 4 1 0
MRI 1y ND 1
ND, Not done. *Note that of the 5 arm 1 animals, 1 had bacterial endocarditis and did
not survive the full 52 weeks. However, calcification was identified as present in veg-
etations, and therefore it can be stated that all arm 1 animals had calcification at some
point during the course of the study. yOnly 1 animal in arm 1 underwent MRI, whereas
all 5 animals in arm 3 underwent MRI. The arm 2 calcifications were associated with
the suture lines in 2 animals and the conduit wall near the distal suture line in 1 animal
but never in leaflets. For arm 3, the single calcification occurrence was localized to the
proximal suture line and not the leaflets. No decellularized leaflets (n¼ 10, arms 2 and
3) calcified.gery c April 2009
Hopkins et al Congenital Heart DiseaseFIGURE 1. Histology of cryopreserved pulmonary valve allograft explanted at 52 weeks. A,Micrograph depicting the presence of dystrophic calcification at
the base of the cusp extending into the wall of the pulmonary artery. (Original magnification 1003, von Kossa stain.) B, Histologic section demonstrating the
loss of cuspal cellularity after 12 months of implantation. (Original magnification 1003, hematoxylin and eosin.)The Journal of Thoracic and C
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part done to retest the sensitivity and specificity of the 20-
week model and once again has demonstrated its value.
Decellularization seemed to retain the advantages (eg, op-
timal design and excellent tissue properties) of traditional
cryopreserved allografts while postponing or eliminating
the quintessential marker for deterioration: calcification.
Calcific failure is particularly troublesome when homografts
are used in younger patients, and as such, its absence is
a marker for possible prolonged durability. Prolonged dura-
bility is the rationale for and theoretic advantage of antigen
reduction thorough decellularization. Lack of calcification in
these studies suggests better performance but does not guar-
antee lifelong durability. Decellularized valves (arms 2 and
3) calcified less frequently and to a lesser extent than the tra-
ditional cryopreserved (so called viable) valves. Arm 3 test
valves performed far more favorably than arm 1 valves
and somewhat better than their arm 2 counterparts assessed
at 20 and 52 weeks. This might be explained by some hydro-
lysis of the extracellular matrix during saline storage at 4C
(arm 2), which was obviated with glycerolization at80Cpotential for biologic heart valve prostheses.7 These investi-
gators were well aware of the limitations of traditional
methods, such as subcutaneous implants. A working valve
in the bloodstream is in a very specific milieu. The utility
and reliability of this model has consistently been reaf-
firmed, and thus it remains an obligatory preclinical test,
as defined in the US Food and Drug Administration Replace-
ment Heart Valve Guidance documents (US Department of
Health and Human Services, 1994). This was further evi-
denced by our observations of valve dysfunction, calcifica-
tion, or both occurring within 20 weeks for classically
cryopreserved valves. In actuality, this 1-year study con-
firms that the vast majority of information is learned by 20
weeks; this supports the more commonly performed 20-
week time interval as the standard when truly juvenile (pre-
pubescent) sheep are used. When correlated with the explant
pathology, there were no false-positive results for echocar-
diographic identification of calcium (Figure 4). We are not
aware of any other report for a 1-year duration of implanta-
tion in which serial in vivo functional imaging studies allow
comparison of 20-week and 52-week calcification data. Al-FIGURE 2. Histology of decellularized a pulmonary valve allograft explanted at 52 weeks. A, Low-magnification view depicting the recellularization of the
pulmonary artery and basal region of the cusp. Pannus is seen on the luminal surface of the pulmonary artery extending onto the inflow surface of the cusp.
Note the presence of focal endothelialization on the outflow surface of the cusp. (Original magnification 1003, hematoxylin and eosin.) B, Higher-magni-
fication view showing rare focal sites of recellularization of the cusp. (Original magnification 2003, Movat pentachrome stain [collagens, yellow; elastic
fibers, black.])ardiovascular Surgery c Volume 137, Number 4 911
Congenital Heart Disease Hopkins et al
C
H
DFIGURE 3. Immunohistochemistry of decellularized pulmonary valve allograft explanted at 52 weeks. A, Basal region of the cusp and pannus on the luminal
surface of the pulmonary artery depicting the presence of a-smooth muscle actin–immunoreactive cells (green). 40-6-Diamidino-2-phenylindole dihydro-
chloride–stained nuclei are shown in blue. (Original magnification 1003.) B, Histologic section of the pulmonary artery demonstrating the extent of recellu-
larization by heat shock protein 47 (collagen chaperon protein with obligatory expression when cells are actively synthesizing new collagen)–immunoreactive
cells in the arterial wall and within pannus on the luminal surface. Heat shock protein 47 indicates active collagen synthesis. Together, heat shock protein 47
and a-smoothmuscle actin suggest a myofibroblast phenotype consistent with valve interstitial cells. 40-6-Diamidino-2-phenylindole dihydrochloride–stained
nuclei are shown in cyan. (Original magnification 2003.)912 The Journal of Thoracic and Cardiovascular SuPreviously, we have detailed a PRA assay for monitoring
immune responses within the juvenile ovine cardiac valve
chronic implant model. Animals were treated with antibi-
otics for each serum sampling during that 20-week study.11
Antibiotics were not administered throughout this longer
study to ensure the health of the animals. Without antibiotic
suppression, data from the PRA assay were highly scattered
and without recognizable patterns. As ruminants with 4-part
stomachs, sheep contain a large bacterial/fungal load in the
blood and gastrointestinal tract that maintains the animals
in an almost constant low-level inflammatory state.14 There-
fore this assay seems to be an unreliable tool for application
in longer-term juvenile ovine studies.15-21
The explant histopathology findings exemplified in Figures
1 to 3 will be explored more quantitatively and reported sepa-
rately. Qualitatively, the autologous in vivo cell in-migration
into the sinus and pulmonary artery wall appears to progress
with phenotypically appropriate cells. These cells might
block/prevent the inflammation and scar healing responses
typically seen in cryopreserved homografts or xenograft
valves.13,16,22-27 However, none of the valves underwent sig-
nificant leaflet recellularization beyond the cusp base (where
adventitial wall cell in-migration could reach). This lack of
leaflet recellularizationmight limit the long-term performance
because lifelong durability presumably depends on leaflet
valve interstitial cells actively resynthesizing structural protein
for constructive and adaptive remodeling of the valve matrix.
The primary end point of this study was valve deteriora-
tion, as marked by calcifications. Conduit valve dysfunction
inexorably follows as a consequence of biologic deteriora-
tion. Leaflet dysfunction is correlated with calcification.
The echocardiographic, cardiac catheterization, and direct
dimension measurements were internally consistent; the
few hemodynamic differences were not great and did not
reflect severe stenosis/regurgitation hemodynamics or the(arm 3). Alternatively, the high osmotic gradient established
during glycerol treatment might have further extracted anti-
genic material, including cell-wall fragments, proteins, lipo-
proteins, and lipopolysaccharides.
Although effective in preventing or postponing conduit
wall and leaflet calcifications, decellularization did not to-
tally protect against suture line (anastomotic) calcifications
(Table 3). Presumably, surgical injury to native tissue was
in itself proinflammatory, occasionally provoking fibrocalci-
fication independent of the transplanted tissue type. This in-
dicates the sensitivity of sheep tissue to any cell injury or
necrosis, typically responding with calcification of the af-
fected tissue.
FIGURE 4. Echocardiogram of juvenile sheep. Sagittal view of right
ventricular outflow tract traditional, clinically analogous, cryopreserved
allograft obtained 20 weeks after implantation. Note calcium in the leaflets
(circles) and conduit walls (arrows).rgery c April 2009
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sistent with clinical experience in which right ventricular
outflow tract conduit deterioration can be significantly
advanced before hemodynamic deterioration is manifest.
In its limited application in this study, MRI did not signifi-
cantly add to information acquired by means of serial
echocardiographic analysis, explant pathology (including
specimen radiographic analysis), and terminal cardiac cath-
eterization with angiographic analysis. Cost and the need for
an additional anesthetic episode mitigate its appeal in
chronic valve performance testing. With its easier applica-
tion and serial capability, 3-dimensional echocardiographic
analysis might be a more appealing functional test than
MRI. Transthoracic echocardiographic analysis is techni-
cally difficult once the sheep grow to greater than 150 lbs.
Thus transesophageal echocardiography after light anesthe-
sia is a more reliable method.
This experiment was designed to compare decellularized
valves with the most widely used nonmanufactured clinical
valve, the cryopreserved homograft, thus testing ‘‘homo-
grafts’’ that have been altered in biologic content rather
than functional design. The central question was whether de-
cellularization retains the advantages of traditional cryopre-
served allografts while prolonging durability by reducing
calcifications. This hypothesis is affirmed. The surgical, he-
modynamic, and performance advantages of homograft
valves seem to be preserved with the antigen-reduced decel-
lularized valves. If, with experience, clinical durability is
demonstrated, as implied by these results in juvenile sheep,
then a decellularized homograft valve might truly be an im-
proved homograft for use in the right ventricular outflow
tract, although the lack of leaflet recellularization by 52
weeks is of concern as a potential long-term hazard. If safety
is demonstrated with clinical use, such decellularized valves
might also be candidates for use as extracellular matrix scaf-
folds for bioreactor-based cell-seeding strategies, creating
recellularized tissue-engineered heart valves.6,28,29
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DFIGUREE1. Body surface area (BSA) distribution per treatment over time
for weeks 10, 20, 35, and 52. Box plots of 1 years’ growth (body surface
area) for each arm are shown, with individual points per treatment at weeks
10, 20, 37, and 52. Means are connected. There were no significant differ-
ences in the rates of growth among the 3 arms over time (P ¼ .145).Week
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FIGURE E2. Ovine panel reactive antibody scatter plots over the 1-year study. Scatter plots of panel reactive antibody data for 3 arms over the course of 52
weeks are shown: A, major histocompatibility complex I; B, major histocompatibility complex II. The range of points could not be statistically fit.MFI, Mean
fluorescence intensity.913.e1 The Journal of Thoracic and Cardiovascular Surgery c April 2009
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DTABLE E1. Echocardiographic Doppler gradients
Peak gradient
(mm Hg)
Mean gradient
(mm Hg) EOA (cm2) EOA/BSA
Time (wk) No. Mean SD Mean SD No. Mean SD Mean SD
10
Arm 1 5 7.12 6.22 2.82 1.81 5 5.78 2.31 5.64 1.96
Arm 2 4 5.45 1.41 2.08 0.68 5 4.54 1.22 4.89 2.08
Arm 3 4 2.60 0.67 1.50 0.51 5 5.90 0.78 4.87 0.81
20
Arm 1 4 4.83 3.49 2.15 1.31 4 5.58 2.22 4.65 1.19
Arm 2 4 4.28 2.27 1.83 1.07 4 4.83 0.76 3.99 0.52
Arm 3 4 3.30 0.48 1.85 0.47 5 6.04 0.98 4.58 1.06
37
Arm 1 4 4.75 1.85 2.18 0.97 4 6.13 3.14 4.54 1.90
Arm 2 4 4.30 1.89 2.08 0.94 4 5.05 1.15 4.20 0.75
Arm 3 5 3.40 1.69 1.84 0.77 5 6.58 1.11 4.49 1.21
52
Arm 1 1 2.90 * 1.50 * 3 6.53 3.39 4.49 2.15
Arm 2 1 4.90 * 10.4 * 3 4.90 0.96 3.75 0.74
Arm 3 5 3.08 1.26 1.60 0.50 5 6.58 0.61 4.40 0.97
No differences were detected between groups for gradients or effective orifice area measurements.EOA, Effective orifice area; BSA, body surface area; SD, standard deviation. *N¼
1 for these time points because of technical difficulties in acquiring transthoracic echocardiographic windows in the large 1-year old sheep, and therefore no standard deviation was
determined.C
HTABLE E2. Cardiac catheterization data
Arm 1
(n ¼ 4)
Arm 2
(n ¼ 4)
Arm 3
(n ¼ 5)
P
value
Arm 1
(n ¼ 4)
Arm 2
(n ¼ 4)
Arm 3
(n ¼ 5)
P
value
Cardiac output (mL/min) RV mean pressure
(mm Hg)
Mean 5750 5100 4680 Mean 12.75 9.25 18.2
SD 2007 2986 756 .740 SD 2.75 1.71 2.95 .001
Cardiac index
(L $ min1 $ m2)
PA pressure, systolic
(mm Hg)
Mean 4.88 4.18 3.62 Mean 21.0 14.8 28.2
SD 1.67 2.36 0.79 .548 SD 5.10 5.12 6.87 .021
Gorlin EOA (cm2) PA pressure, mean
(mm Hg)
Mean 2.16 2.56 1.76 Mean 13.0 9.25 19.6
SD 0.75 2.05 0.29 .626 SD 2.58 1.26 3.78 .001
EOA index
(EOA/BSA; cm2/m2)
PA pressure, diastolic
(mm Hg)
Mean 1.54 1.84 1.17 Mean 7.25 4.50 11.60
SD 0.39 1.44 0.28 .507 SD 0.96 1.91 2.88 .002
RV, systolic (mm Hg) Mean transvalvular
gradient (mm Hg)
Mean 21.5 14.25 27.0 Mean 0.00 0.25 0.80
SD 5.26 5.91 5.15 .018 SD 0.00 0.50 0.45 .032
RV, diastolic (mm Hg) Peak transvalvular
gradient (mm Hg)
Mean 6.25 5.00 11.2 Mean 0.75 0.50 3.20
SD 2.06 1.63 3.03 .007 SD 1.50 0.58 2.86 .129
P values are listed for any arm differences for each given parameter. Tukey post-hoc comparisons were subsequently applied to determine where differences occurred. Differences
tended to be biologically benign (eg, although mean transvalvular gradients were statistically different, the range was 0.0–0.8 mm Hg across the arms). SD, Standard deviation; RV,
right ventricular; PA, pulmonary artery; EOA, effective orifice area; BSA, body surface area.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 4 913.e2
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DTABLE E3. Directly measured implant versus explant valve conduit
dimensions
Variable Arm Mean (mm) SD No.
Implant native
main PA diameter ED
1 17.0 1.6 5
2 17.6 1.1 5
3 16.8 0.4 5
Implanted graft length 1 26.4 1.1 5
2 25.0 1.6 5
3 23.8 0.8 5
Explant conduit length 1 26.9 11.7 3
2 27.9 3.5 4
3 30.3 6.1 4
Implant proximal
anastomosis diameter
1 21.5 2.1 5
2 22.2 2.6 5
3 22.6 1.5 5
Explant proximal
anastomosis diameter
1 21.4 3.5 4
2 53.8 18.1 4
3 22.0 1.9 5
Implant distal
anastomosis diameter
1 21.4 2.5 5
2 21.8 2.8 5
3 23.0 0.9 5
Explant distal
anastomosis diameter
1 30.8 13.5 4
2 54.5 3.1 4
3 21.7 1.2 5
One outlier in arm 2 resulted from an animal that had leaflet dysfunction from subvalv-
ular distortion at the suture line. Accordingly, the distal asymmetric enlargement (in-
cluding the sinotubular junction, distal anastomosis, and distal native pulmonary
artery) was due to jetting and not growth or diffuse aneurysmal dilation. Taking this
finding into account, by means of univariate testing, including the F test for 1-way gen-
eralized linear models comparing means for arm 1 with arm 3, there were no differ-
ences in the directly measured implant pulmonary artery diameters, proximal and
distal anastomosis diameters, and the explant conduit length measurements. SD, Stan-
dard deviation; PA, pulmonary artery; ED, end diastolic.
Appendix E1. Valve decellularization methodology.
Valve conduits were treated with an anionic nondenaturing
detergent (N-lauroyl sarcosinate; Sigma, St Louis, Mo) in
a Tris buffer solution (recirculated at room temperature for
24 hours) containing a recombinant endonuclease (Benzo-
nase; EMD BioSciences, Gibbstown, NJ), lincomycin,
polymyxin B, and vancomycin. After detergent and endonu-
clease treatment, the valve conduits were rinsed (at room
temperature) by recirculating water through a bed of anion
exchange resin and hydrophobic adsorbent resin for 24
hours. The valves were either removed from the decellulari-
zation chamber and placed into isotonic saline with
polymyxin B or underwent glycerolization for 24 hours
(LifeNet Health; US Patents 6,743,574 and 6,432,712).
After processing, storage was at less than110C for the
standard cryopreserved valves, 1C to 10C for the decellu-
larized saline–stored valves, and80C for the decellular-
ized glycerolized valves.
Appendix E2. Ovine echocardiographic protocol
A short-axis view of the base of the heart near the level
of the right ventricular outflow tract and implanted valve
was used for initial orientation. Internal diameters of the913.e3 The Journal of Thoracic and Cardiovascular Surproximal distal anastomosis, as well as the valve annulus,
were measured during systole by means of 2-dimensional
echocardiographic analysis. The presence and severity of
regurgitation through the implanted test valve was evalu-
ated by means of color flow Doppler imaging. Severity
of regurgitation was classified as follows: trace (1þ), regur-
gitant jet is limited to the immediate valve area; mild (2þ),
jet limited to the right ventricular outflow tract; moderate
(3þ), jet extending into the right ventricular cavity; and se-
vere (4þ), jet extended to the tricuspid valve. The peak
pressure gradient across the implanted valve was measured
by means of continuous-wave Doppler imaging. A paraste-
nal short-axis view of the left ventricle at the midpapillary
muscle level was obtained to measure ejection fraction,
and stroke volume was obtained by using the Teicholz
method. The EOA was determined by using a modified
continuity equation, assuming that stroke volume was
equal in the right and left ventricles so that EOA is defined
as left ventricular stroke volume divided by volume thick-
ness index. All echocardiographic images were obtained
by one operator and reviewed by a second operator for ac-
curacy. Valves were also qualitatively evaluated for appar-
ent thickness of the leaflets, stiffness of the leaflets, and
presence or absence of calcifications in the leaflets or con-
duit wall.
Appendix E3. Ovine PRA protocol
Serum was run through a HiTrap purification system
(Amersham Biosciences, Buckinghamshire, United King-
dom). Purified serum was incubated with beads (One
Lambda, Inc, Canoga Park, Calif) tagged with 30 major
histocompatibility complex I and 30 major histocompatibil-
ity complex II HLA antigens for 30 minutes in the dark with
continuous gentle shaking. The beads were washed with
buffer solution and centrifuged at 11,500 rpm for 2 minutes.
The supernatant was removed, and the beads were incubated
with a rabbit antisheep fluorescein isothiocyanate–labeled
antibody (Jackson Immuno-Research, West Grove, Pa) for
30 minutes in the dark with continuous shaking. The beads
were washed with buffer solution and centrifuged at 11,500
rpm for 2 minutes. The supernatant was removed, and the
beads were fixed at 0.5% paraformaldehyde and analyzed
on a Becton Dickinson FACS flow cytometer (Becton Dick-
inson, Franklin Lakes, NJ). Human positive and negative
controls were used for calibration. FL1 histograms were
obtained for all specimens. Results are reported as the per-
centage of beads fluorescing, and positive responses were
defined based on recommended ranges by One Lambda, as
in clinical use.
Appendix E4. Ovine cardiac catheterization assessment
of valve EOA protocol
With fluoroscopic guidance (EOC 9600 C-Arm, vascular
package) and with the sheep under light sedation, an 8Fgery c April 2009
Hopkins et al Congenital Heart DiseaseSwan–Ganz catheter was inserted through the left jugular
vain and correctly positioned with the tip in the distal
main pulmonary artery.
Thermodilution cardiac outputs were obtained in triplicate
on 3 separate occasions, averaged, and normalized to body
surface area by using the Haycock formula. The Swan–
Ganz catheter was exchanged for a single hole–tipped cathe-
ter, and 3 pullback pressure gradients were obtained across
the test valve. EOA values were calculated with the classical
Gorlin equation and indexed to body surface area values.12
Appendix E5. Ovine angiographic protocol
After pressures were measured, angiographic analysis
was performed to record images of the functioning valve.
Power injections (BV Pulsera; Phillips, Andover, Mass) of
contrast (75–99 mL total at 25–33 mL/s with 1-second in-
crease) were made in the outflow portion of the right ventri-
cle below the valve conduits to assess stenosis, leaflet
motion, and ventricular function, and second injectionsThe Journal of Thoracic and Cawere made in the main pulmonary artery above the test
valves to assess regurgitation.
Appendix E6. Ovine MRI protocol
A long-axis cine image with steady-state free precession
MRI was obtained, including 2-chamber, 4-chamber, 3-
chamber, and coronary obliques, by using a 1.5-Tesla Mag-
net (General Electric, Sigma Horizon LX, Milwaukee, Wis).
A short-axis cine image from the base to the apex was ob-
tained for volume and ejection fraction calculations. The ve-
locity encoding gradient was set to 120 cm/s. For pulmonary
valve imaging, cine steady-state free precession was posi-
tioned off axial scouts in the sagittal and oblique planes
through the main pulmonary artery. The second cine plane
was perpendicular to the first plane through the test valve.
A phase contrast was obtained through the plane at the pul-
monary valve by positioning perpendicular to the previous
plane. The velocity-encoding gradient was reset to approxi-
mately 110 cm/s, as necessary.rdiovascular Surgery c Volume 137, Number 4 913.e4
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